CORBF vs. TOI, DCGO, XGN, EUDA, SERA, QIPT, NAKA, KDLY, ATPC, and OPGN
Should you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Oncology Institute (TOI), DocGo (DCGO), Exagen (XGN), EUDA Health (EUDA), Sera Prognostics (SERA), Quipt Home Medical (QIPT), KindlyMD (NAKA), Kindly MD (KDLY), Agape ATP (ATPC), and OpGen (OPGN). These companies are all part of the "healthcare" industry.
Global Cord Blood vs. Its Competitors
Oncology Institute (NASDAQ:TOI) and Global Cord Blood (NYSE:CORBF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.
Oncology Institute has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of -0.52, suggesting that its stock price is 152% less volatile than the S&P 500.
Global Cord Blood has a net margin of 0.00% compared to Oncology Institute's net margin of -15.38%. Global Cord Blood's return on equity of 0.00% beat Oncology Institute's return on equity.
Global Cord Blood has lower revenue, but higher earnings than Oncology Institute.
36.9% of Oncology Institute shares are held by institutional investors. 8.5% of Oncology Institute shares are held by insiders. Comparatively, 0.5% of Global Cord Blood shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Oncology Institute presently has a consensus target price of $6.50, indicating a potential upside of 101.24%. Given Oncology Institute's stronger consensus rating and higher possible upside, research analysts clearly believe Oncology Institute is more favorable than Global Cord Blood.
In the previous week, Oncology Institute had 5 more articles in the media than Global Cord Blood. MarketBeat recorded 5 mentions for Oncology Institute and 0 mentions for Global Cord Blood. Oncology Institute's average media sentiment score of 0.52 beat Global Cord Blood's score of 0.00 indicating that Oncology Institute is being referred to more favorably in the media.
Summary
Oncology Institute beats Global Cord Blood on 10 of the 14 factors compared between the two stocks.
Get Global Cord Blood News Delivered to You Automatically
Sign up to receive the latest news and ratings for CORBF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CORBF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CORBF vs. The Competition
Global Cord Blood Competitors List
Related Companies and Tools
This page (NYSE:CORBF) was last updated on 7/17/2025 by MarketBeat.com Staff
Free CORBF Stock Alerts